[
  {
    "ts": "2025-12-29T21:40:00+00:00",
    "headline": "Royalty Pharma Acquires Remaining Royalty Interest in Roche’s Evrysdi for $240 Million and Potential Milestones",
    "summary": "Royalty Pharma will now own 100% of the 8% to 16% Evrysdi royalty following multiple transactions with PTC since 2020NEW YORK, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired the final portion of PTC Therapeutics’ remaining royalty on Roche’s Evrysdi for $240 million upfront and up to $60 million in sales-based milestones. Evrysdi, marketed by Roche, is an orally administered survival motor neuron-2 (SMN2) splicing modifier for the treatme",
    "url": "https://finance.yahoo.com/news/royalty-pharma-acquires-remaining-royalty-214000306.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "75db10cd-c5bb-30f9-9483-0d5d9f94d0f1",
      "content": {
        "id": "75db10cd-c5bb-30f9-9483-0d5d9f94d0f1",
        "contentType": "STORY",
        "title": "Royalty Pharma Acquires Remaining Royalty Interest in Roche’s Evrysdi for $240 Million and Potential Milestones",
        "description": "",
        "summary": "Royalty Pharma will now own 100% of the 8% to 16% Evrysdi royalty following multiple transactions with PTC since 2020NEW YORK, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired the final portion of PTC Therapeutics’ remaining royalty on Roche’s Evrysdi for $240 million upfront and up to $60 million in sales-based milestones. Evrysdi, marketed by Roche, is an orally administered survival motor neuron-2 (SMN2) splicing modifier for the treatme",
        "pubDate": "2025-12-29T21:40:00Z",
        "displayTime": "2025-12-29T21:40:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/d4dc9c9f0a11200f9e82d2cebec20597",
          "originalWidth": 340,
          "originalHeight": 21,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/JJyMfvI7hR4Q.IxJ8t4VJA--~B/aD0yMTt3PTM0MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/d4dc9c9f0a11200f9e82d2cebec20597.cf.webp",
              "width": 340,
              "height": 21,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/1.HLX9VzftZjdnXHrtF1QA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/d4dc9c9f0a11200f9e82d2cebec20597.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/royalty-pharma-acquires-remaining-royalty-214000306.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/royalty-pharma-acquires-remaining-royalty-214000306.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "RPRX"
            },
            {
              "symbol": "RHHBF"
            },
            {
              "symbol": "PTC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]